<DOC>
	<DOC>NCT00252811</DOC>
	<brief_summary>This is a Phase II, randomised, double-blind, placebo-controlled study. Subjects with histologically-confirmed oestrogen receptor negative (ER-), progesterone receptor negative (PgR-) primary breast cancer breast cancer will be randomly assigned in a 2:1 ratio to receive ZD1839 250 mg once daily or matching placebo for a total period of 5 weeks. Surgical intervention will take place after 4 weeks (on Day 29) and treatment will continue for 1 week after surgery.</brief_summary>
	<brief_title>A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologicallyconfirmed ER and PgR primary breast cancer Stage T .5 cm, N01, M0 No previous treatment for breast cancer ALT or AST greater than 2.5 times the ULRR Metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>